Project: Rational antithrombotic use in an atrial fibrillation population
2019-11-01 – 2023-10-04
- Abstract
The associated challenges of an ageing population for social welfare systems and individual healthy aging necessitate more research into effective prevention and rational treatment strategies. Besides the importance of identifying vulnerable elderly in an aging population to better outweigh benefits and risks of invasive procedures or potentially harmful medication, there remains a large knowledge gap in understanding the impact of age-related pharmacological changes and multimorbidity to the intended therapeutic value of several medications. This is particularly important for medicines for which the benefits need to be weighed against important associated risks, as with antithrombotics. Therefore, more fundamental research providing evidence to support the rational use of antithrombotics is needed. The overall aim of my PhD project proposal is to study rational antithrombotic use in terms of effectiveness and safe use in a real-life population with atrial fibrillation. By studying the use and impact of antithrombotic treatment in real-life multimorbid subjects with atrial fibrillation using different kinds of medication, we want to unravel the determinants of treatment success in terms of prevention of thromboembolisms and enhance insight in the optimal use of these drugs in terms of preventing (major) bleeding complications in the community population with comorbidities and polypharmacy.
-
- Journal Article
- A1
- open access
Minimal adherence threshold to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death : a nationwide cohort study
-
- Journal Article
- A1
- open access
Pharmacodynamic drug-drug interactions and bleeding outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants : a nationwide cohort study
-
- Journal Article
- A1
- open access
The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
-
- Journal Article
- A1
- open access
Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation : a nationwide cohort study
-
- Journal Article
- A1
- open access
Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants : a nationwide cohort study
-
Rational oral anticoagulant use in patients with atrial fibrillation
(2023) -
- Journal Article
- A1
- open access
Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation : a nationwide cohort study
-
- Journal Article
- A1
- open access
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019 : a nationwide cohort study
-
- Journal Article
- A2
- open access
Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants : a nationwide cohort study
-
- Journal Article
- A1
- open access
Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists : a Belgian nationwide cohort study